Quick Answer
ZyVersa Therapeutics, Inc. reported Common Stock Shares Outstanding of 8.10 million shares for the year ending 2025.
- ZyVersa Therapeutics, Inc. showed an increase of +222.8% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from ZyVersa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: 9.21 million shares | Q2 2023: 23.67 million shares | Q3 2023: 43.52 million shares | Q1 2024: 834,896 shares | Q2 2024: 834,896 shares | Q3 2024: 1.07 million shares | Q1 2025: 2.57 million shares | Q2 2025: 4.87 million shares | Q3 2025: 8.10 million shares.
- Over the full 4 years of available data (2022 to 2025), ZyVersa Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 3,042.8%.
- Historical annual values: Fiscal year 2025: 8.10 million shares | Fiscal year 2024: 2.51 million shares | Fiscal year 2023: 402,205 shares | Fiscal year 2022: 257,604 shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: